NCT02221089View on ClinicalTrials.gov

Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

July 31, 2014

Conditions
Imparied Retinal Vascular ReactivityHealthy Subjects
Interventions
DRUG

Escherichia coli Endotoxin

dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.

DIETARY_SUPPLEMENT

Retaron®

Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days

OTHER

Placebo

Placebo capsules identical in appearance to Retaron capsules

Trial Locations (1)

1080

Department of clinical Pharmacology, Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02221089 - Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans | Biotech Hunter | Biotech Hunter